Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
By A. Grothey, D. Sargent, R. Goldberg, H. Schmoll. Journal of Clinical Oncology, 2004
1,099 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/420fe2ee4857ae9501b11fd4e2a103d076220c0b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. (2007, background): “the proportion of patients who received all the three active drugs in the course of their disease, but not with the proportion of patients who received any second-line therapy.(9) This analysis also shows that, in a sequential strategy, not all patients who progress after first-line chemotherapy are”
- Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). (2008, background): “Although previous reports have emphasized that OS in mCRC is associated with exposure to all available active cytotoxic agents, and that the addition of bevacizumab to either first- or second-line chemotherapy prolongs survival, questions remain regarding the optimal use and sequencing of these agen”
- EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. (2008, background): “The effect of poststudy therapies on early-line clinical trials in mCRC is not unprecedented,(24) with some authors questioning the reliability of OS versus PFS as end point in early therapy settings.(8,25) Survival was the appropriate choice as primary end point for a trial designed to affect clini”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, methodology): “Both regimens consist of a 46- to 48-h administration every 2 weeks (q 2 weeks) with a bolus of 5-FU administration (LV5FU2) regimens [6, 7].”
- Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients (2019, background): “INTRODUCTION Chemotherapy is still considered the backbone of anticancer therapy and has improved the life expectancy of countless patients (1, 2).”
- Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. (2005, background): “While infusional 5-fluorouracil (5-FU) [7] or the combination of 5-FU/folinic acid (FA) [8, 9] result in response rates of <25% and a median overall survival of about 12 months, combination chemotherapy including modulated infusional 5-FU plus irinotecan and oxaliplatin, can achieve a response rate ”
- Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. (2007, background): “ivery of the Y90 microspheres and be the authorized user, nd (5) monitor radiation safety.”